Deka Bank Deutsche Girozentrale Akebia Therapeutics, Inc. Transaction History

Deka Bank Deutsche Girozentrale

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$2.26 - $3.34 $230,745 - $341,014	-102,100 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$2.39 - $13.08 $244,019 - $1.34 Million	102,100 New	102,100 $239,000
Q4 2019 Feb 04, 2020	SELL	$3.16 - $6.73 $464,836 - $989,983	-147,100 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $628,705 - $956,340	-177,100 Reduced 54.63%	147,100 $606,000
Q2 2019 Aug 01, 2019	BUY	$4.1 - $8.05 $1.24 Million - $2.44 Million	303,600 Added 1473.79%	324,200 $1.5 Million
Q1 2019 May 10, 2019	BUY	$5.41 - $8.73 $18,935 - $30,555	3,500 Added 20.47%	20,600 $170,000
Q4 2018 Feb 12, 2019	SELL	$5.39 - $9.15 $18,865 - $32,025	-3,500 Reduced 16.99%	17,100 $95,000
Q1 2018 May 03, 2018	BUY	$9.53 - $15.68 $196,318 - $323,008	20,600 New	20,600 $201,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $353M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.